Plain English Summary
Background and study aims
The aim of this study is to assess the perception of patients towards three different treatment options for the palliative treatment of cancer which has spread within the abdominal cavity (disseminated peritoneal adenocarcinoma). Adjuvant chemotherapy involves medication (chemotherapy) being given in addition to surgery in order to reduce the risk of the cancer coming back. Pressurised intra peritoneal aerosol chemotherapy (PIPAC) involves chemotherapy being sprayed in the abdomen, while hyperthermic intraperitoneal chemotherapy (HIPEC) involves heated chemotherapy treatment delivered directly to the abdomen. PIPAC is currently only able to be offered to patients in a limited feasibility capacity.
Who can participate?
Patients aged over 18 who are being treated with adjuvant chemotherapy, HIPEC or PIPAC for disseminated peritoneal adenocarcinoma
What does the study involve?
Participants are interviewed about their perspective and attitudes to the treatment option and their quality of life is assessed before treatment starts and for up to 3 months during treatment. Demographic data is collected from those patients who are offered PIPAC to determine if there are any factors associated with take up of the new treatment.
What are the possible benefits and risks of participating?
In order to allow future research and expansion of the treatment options available for patients, it is important to understand patients’ concerns, questions and expectations before and how they may change following treatment. This study will enable the development of patient information material for future studies and also to identify which patient groups (if any) are more or less likely to opt for new/innovative treatments.
Where is the study run from?
1. Cwm Taf University Health Board (UK)
2. Cardiff and Vale University Health Board (UK)
When is the study starting and how long is it expected to run for?
September 2017 to November 2018
Who is funding the study?
Tenovus (UK)
Who is the main contact?
Julie Cornish
Trial website
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
1.0
Study information
Scientific title
Patient Perspectives on Peritoneal Metastasis Treatments
Acronym
PerMeT
Study hypothesis
The trialists will approach all patients found to have intraperitoneal adenocarcinoma who are being considered for one of the three treatments (palliative chemotherapy, ePIPAC or HIPEC).
The aim of this study is to assess patient attitudes and perspectives on new innovations for cancer surgery before and after treatment. In addition information on key concerns of patients around each treatment option will be captured.
Ethics approval
Wales REC, 14/09/2017, ref: 17/WA/0247
Study design
Qualitative study
Primary study design
Observational
Secondary study design
Qualitative study
Trial setting
Hospitals
Trial type
Quality of life
Patient information sheet
Not available in web format, please use contact details to request a patient information sheet
Condition
Adenocarcinoma with peritoneal metastases
Intervention
4-8 patients are recruited from each of the three treatment groups:
1. Adjuvant chemotherapy
2. HIPEC (hyperthermic intraperitoneal chemotherapy)
3. PIPAC
Over a 12-month period face to face interviews are performed and quality of life data are collected before treatment commences and for up to 3 months during treatment. Baseline demographic data of those patients being offered PIPAC are collected to determine if there are any associated factors with take up of the new treatment.
Intervention type
Other
Phase
Drug names
Primary outcome measure
Patient’s perspective and attitudes to the treatment option, assessed using qualitative interviews and focus groups at baseline and 3 months
Secondary outcome measures
1. Quality of life, measured using EQ5D
2. Personality profile of the patient and attitude of risk, assessed using Ten Item Personality inventory
3. Side effects experienced, assessed using patient diary and qualitative interviews
Measured at baseline and 3 months, with the patient diary also being assessed at 6 weeks
Overall trial start date
01/09/2017
Overall trial end date
01/11/2018
Reason abandoned (if study stopped)
Participant recruitment issue
Eligibility
Participant inclusion criteria
1. Patients with disseminated peritoneal adenocarcinoma (of ovarian or colorectal origin)
2. Patients who are due to undergo treatment with; palliative chemotherapy OR HIPEC (Hyperthermic intraperitoneal chemotherapy) OR ePIPAC (electrostatic pressurised intra peritoneal aerosol chemotherapy)
3. Patients >18 years of age
4. Patients who are able to give informed consent
Participant type
Patient
Age group
Adult
Gender
Both
Target number of participants
8-12 per group (max 24)
Participant exclusion criteria
Unable to give informed consent
Recruitment start date
01/10/2017
Recruitment end date
01/10/2018
Locations
Countries of recruitment
United Kingdom
Trial participating centre
Cwm Taf University Health Board
Royal Glamorgan Hospital
Llantrisant
CF72 8XR
United Kingdom
Trial participating centre
Cardiff and Vale University Health Board
Cardiff
CF14 4XW
United Kingdom
Funders
Funder type
Charity
Funder name
Tenovus
Alternative name(s)
Tenovus Cancer Care
Funding Body Type
private sector organisation
Funding Body Subtype
other non-profit
Location
United Kingdom
Results and Publications
Publication and dissemination plan
Publication and dissemination plan as of 15/11/2018:
A final report will be published through Tenovus, the charity that funded the study.
Previous publication and dissemination plan:
Planned submission of the protocol for publication in the next 3 months. Planned publication of the results in a high impact peer reviewed journal around one year after the end of the trial.
IPD sharing statement
The data sharing plans for the current study are unknown and will be made available at a later date.
Intention to publish date
01/11/2019
Participant level data
To be made available at a later date
Basic results (scientific)
Publication list